Global Hemofiltration Basic Solution Market Strategic Research Report

Scope of the Report

The global Hemofiltration Basic Solution market size is predicted to grow from US$ 670 million in 2025 to US$ 1,754 million in 2032; it is expected to grow at a CAGR of 14.9% from 2026 to 2032.

Hemofiltration replacement basic solution is a special drug for continuous blood purification. It is used to replace water and electrolytes in the body during hemofiltration treatment and replace part of the kidney function. The prescription ingredients of this product do not contain potassium ions and lactate, which is convenient for the rapid preparation of bicarbonate hemofiltration basic solution in clinical practice, avoids complications such as lactic acidosis and hyperkalemia, and stabilizes the internal environment of the body to the greatest extent.

The largest manufacturer of hemofiltration basic solution in China is Chengdu Qingshan Likang Pharmaceutical, holds a share over 80%.

Blood purification technology is a new medical technology developed in the late twentieth century on the basis of artificial kidneys for the treatment of chronic renal failure. It is a medical technology that draws the patient's blood out of the body, removes certain pathogenic substances in it through purification devices, purifies the blood, and achieves the purpose of treating certain diseases. It is often used in the treatment of patients with end-stage renal disease (uremia), critical illness, acute poisoning, etc. The basic treatment methods of blood purification include hemodialysis (HD), hemoperfusion (HP) or hemoadsorption (HA), hemofiltration (HF), plasma exchange (PE), immunoadsorption (IA), etc., as well as the combined application of multiple technologies above.

From the perspective of different populations, those over 65 years old account for nearly 44% of the total market size.

From the perspective of product market application, since blood filtration replacement basic fluid is mainly used for blood filtration treatment, most of them are continuous blood filtration at the bedside of critically ill patients in ICU wards. The market size of blood filtration replacement basic fluid for ICU has reached 80%.

This report presents a comprehensive overview of the global Hemofiltration Basic Solution market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Age: above 65
• Age: between 45 and 64
• Age: below 45

Segment by Application

• ICU
• Nephrology
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Hemofiltration Basic Solution market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in ICU, Nephrology, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact